Literature DB >> 22108820

Construction and functional activity of a recombinant vector expressing rat glutamic acid decarboxylase 65.

Jian-Sheng Liu1, Qian Wang, Ji-Bo Zhang, Ling-Ju Kong, Su-Yan Yao, De-Yu Zheng, Qun-Yuan Xu.   

Abstract

OBJECTIVE: Glutamic acid decarboxylase 2 (GAD65) is a gamma-aminobutyric acid (GABA) synthetase. This study aimed to construct a recombinant lentivirus-rGAD65 (rLV-rGAD65) vector containing the cDNA of rat GAD65 (rGAD65) and assess its functional activity in vitro and in vivo.
METHODS: cDNA of rGAD65 was amplified by RT-PCR and subcloned into the LV vector, forming the rLV-GFP-rGAD65 plasmid. The recombinant lentivirus particles (rLV-rGAD65) were packaged by the LV Helper-Free System and the titer was measured. Primary rat lung fibroblasts were transfected with rLV-rGAD65. The expression of rGAD65 in fibroblasts was detected by immunocytochemistry and western blot and the level of GABA in the medium was assessed by high-performance liquid chromatograph (HPLC). In vivo, rLV-rGAD65 was injected into the subthalamic nucleus (STN) of Sprague-Dawley rats using stereotaxic methods, and rGAD65 protein levels in the STN were assessed by immunohistochemistry and Western blot, while the GABA concentration in the substantia nigra pars reticulata (SNr) was assayed by HPLC.
RESULTS: The sequence of rGAD65 cDNA was in accord with that in GenBank. The amino-acid sequence of rGAD65 had no mutations and the titer of rLV-rGAD65 reached 6.8 × 10⁸/mL. The efficiency of infection of fibroblasts was 80%, and the concentration of GABA in the medium was (48.14 +/- 9.35) nmol/L. In vivo, rGAD65 expression was detected in the STN, and the concentration of GABA in the SNr increased from (5.95 +/- 1.09) to (12.44 +/- 3.79) nmol/g tissue.
CONCLUSION: The recombinant LV-GFP-rGAD65 vector was successfully constructed. rLV-rGAD65-infected primary fibroblasts in vitro and the expressed rGAD65 catalyzed the formation of GABA from glutamic acid. In vivo, the concentration of GABA in the SNr was increased after rLV-rGAD65 injection into the STN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108820      PMCID: PMC5560388          DOI: 10.1007/s12264-011-1840-8

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  9 in total

1.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 2.  Experimental models of Parkinson's disease.

Authors:  M F Beal
Journal:  Nat Rev Neurosci       Date:  2001-05       Impact factor: 34.870

3.  Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease.

Authors:  R J Mandel; R O Snyder; S E Leff
Journal:  Exp Neurol       Date:  1999-11       Impact factor: 5.330

Review 4.  Viral vectors for gene therapy.

Authors:  P D Robbins; H Tahara; S C Ghivizzani
Journal:  Trends Biotechnol       Date:  1998-01       Impact factor: 19.536

5.  Subthalamic GAD gene therapy in a Parkinson's disease rat model.

Authors:  Jia Luo; Michael G Kaplitt; Helen L Fitzsimons; David S Zuzga; Yuhong Liu; Michael L Oshinsky; Matthew J During
Journal:  Science       Date:  2002-10-11       Impact factor: 47.728

Review 6.  From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control.

Authors:  Thomas Boraud; Erwan Bezard; Bernard Bioulac; Christian E Gross
Journal:  Prog Neurobiol       Date:  2002-03       Impact factor: 11.685

Review 7.  From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research?

Authors:  C E Gross; T Boraud; D Guehl; B Bioulac; E Bezard
Journal:  Prog Neurobiol       Date:  1999-12       Impact factor: 11.685

Review 8.  Update on Parkinson disease.

Authors:  Andrew Siderowf; Matthew Stern
Journal:  Ann Intern Med       Date:  2003-04-15       Impact factor: 25.391

9.  [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

Authors:  H EHRINGER; O HORNYKIEWICZ
Journal:  Klin Wochenschr       Date:  1960-12-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.